Table I.
Baseline characteristics among Alzheimer’s disease cases and major neurocognitive disorder-free controls
| Pairs, n | AD cases | Controls | p | |
|---|---|---|---|---|
| Age, mean ± SD | 365 | 61.2 ± 5.6 | 61.1 ± 5.6 | 0.245 |
| Male sex, n (%) | 365 | 92 (25.2) | 92 (25.2) | 1.00 |
| GM 3/17, n (%) | ||||
| GM 17/17 | 363 | 72 (19.8) | 39 (10.7) | 0.001 |
| GM 3/17 | 363 | 171 (47.1) | 174 (47.9) | 0.884 |
| GM 3/3 | 363 | 120 (33.1) | 150 (41.3) | 0.027 |
| Anti-HSV1 IgG carriership, n (%) | 354 | 323 (91.2) | 312 (88.1) | 0.215 |
| Anti-HSV IgG level, AU, mean ± SD (n)1 | 102.5 ± 21.4 (326) | 102.7 ± 21.9 (317) | 0.9122 | |
| Anti-HSV IgM carriership, n (%) | 354 | 27 (7.6) | 20 (5.6) | 0.371 |
| APOE risk variant carriership3, n (%) | 332 | 205 (61.7) | 80 (24.1) | <0.001 |
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; GM, γ-marker; HSV, herpes simplex virus; AU, arbitrary units; APOE, apolipoprotein E.
3
APOE ε3/ε4 or APOE ε4/ε4.